KRON(Delisted)
Kronos Bio·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 2
Revenue Beats Expectation
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KRON
Kronos Bio, Inc.
A company that develops therapeutics for cancer by targeting dysregulated transcription
301 Binney Street, 2nd Floor East, Cambridge, MA 02142
--
Kronos Bio, Inc. was incorporated under the laws of the State of Delaware on June 2, 2017. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of new cancer therapies designed to change patient outcomes through precise drug strategies targeting dysregulated transcription.
Company Financials
EPS
KRON has released its 2024 Q4 earnings. EPS was reported at -0.43, versus the expected -0.3, missing expectations. The chart below visualizes how KRON has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KRON has released its 2025 Q1 earnings report, with revenue of 1.86M, reflecting a YoY change of -26.03%, and net profit of -8.36M, showing a YoY change of 72.08%. The Sankey diagram below clearly presents KRON's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
